medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2018, Number 2

<< Back Next >>

Rev Latin Infect Pediatr 2018; 31 (2)

Cytomegalovirus infection in the patient undergoing hematopoietic progenitor transplantation. Case report and literature review

Morayta-Ramírez A, Bonilla-Reyna MA, Martínez-Bustamante ME, Ordoñez-Ortega J, Miranda-Madrazo R, Gutiérrez-Hernández S

Language: Spanish
References: 12
Page: 76-79
PDF size: 204.30 Kb.


ABSTRACT

Hematopoietic progenitor transplantation (HPT) has in recent years been a curative therapeutic option for patients with benign or malignant haematological disorders. Infections are a significant cause of morbidity and mortality, and the etiology and risk of infection vary in relation to the post-transplant stage in which it occurs. Cytomegalovirus infection is a latent risk in the patient undergoing HPT, not all individuals present the same risk of infection or disease; depending on age, type of transplant, myeloablative scheme used, serologic status of donor (D) and recipient (R), and graft-versus-host disease (GVHD). The seroprevalence in the world population for CMV in school-age children is 30%, reaching 80% in the adult population, meaning that serology in the donor and recipient is essential for risk statification as well as to establish prevention measures and timely treatment.


REFERENCES

  1. Chan ST, Logan AC. The clinical impact of cytomegalovirus infection following allogenic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters. Blood Rev. 2017; 31 (3): 173-183.

  2. Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017; 64 (1): 87-91.

  3. Sousa H, Boutolleau D, Ribeiro J, Teixeira AL, Pinho Vaz C, Campilho F et al. Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review. Biol Blood Marrow Tansplant. 2014; 20 (12): 1958-1957.

  4. Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C et al. Infections after tansplantation of bone marrow or peripheral blood stem cells from unrelated donors. Biol Blood Marrow Transplant. 2016; 22 (2): 359-370.

  5. Slade M, Goldsmith S, Romee R, DiPersio JF, Dubberke ER, Westervelt P et al. Epidemiology of infections following haploidentical pheripheral blood hematopoietic cell transplantation. Transpl Infect Dis. 2017; 19 (1): doi: 10.1111/tid.12629.

  6. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15 (10): 1143-1238.

  7. Rowe RG, Guo D, Lee M et al. Cytomegalovirus infection in pediatric hematopoietic stem cell transplant: risk factors for primary infection and cases of recurrent and late infection at single center. Biol Blood Marrow Transplant. 2016; 22: 1275-1283.

  8. Huang YT, Neofytos D, Foldi J, Kim SJ, Maloy M, Chung D et al. Cytomegalovirus infection after CD34+-Selected hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016; 22 (8): 1480-1486.

  9. Verduyn LF, Raymakers R, van Dijk A, van der Wagen L, Minnema MC, Kuball J. Cytomegalovirus status and the outcome of t cell-replete reduced-intensity allogenic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016; 22 (10): 1883-1887.

  10. Rustia E, Violago L, Jin Z, Foca MD, Kahn JM, Arnold S et al. Risk factors and utility of a risk-based algorithm for monitoring cytomegalovirus, Epstein-Barr virus, and adenovirus infections in pediatric recipients after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016; 22 (9): 1646-1653.

  11. Laberko A, Bogoyavlenskaya A, Shelikhova L, Shekhovtsova Z, Balashov D, Voronin K et al. Risk factors for and the clinical impact of cytomegalovirus and Epstein-Barr virus infections in pediatric recipients of TCR-α/β- and CD19-depleted grafts. Biol Blood Marrow Transplant. 2017; 23 (3): 483-490.

  12. Alam MM, Bayoumy M, Ali A, Alali M, Al-enezi B, Abosoudah I. Cytomegalovirus infection in children after bone marrow transplantation: risk factors, clinical aspects and outcomes. Pediatric Infectious Disease. 2016; 8 (1): 1-7.




2020     |     www.medigraphic.com